crypto reports Top Featured snippets

HKEx: The database of integrated fund platform funds was launched, and the database of integrated fund platform funds was announced by HKEx, covering more than 2,000 funds approved by the Hong Kong Securities Regulatory Commission, aiming at improving the information transparency of Hong Kong fund investment products.Lianxiang Co., Ltd. and others set up a new digital technology company. The enterprise search APP shows that recently, Zhejiang Lianxi Digital Technology Co., Ltd. was established, with Li Xiaoliang as the legal representative and a registered capital of 10 million yuan. Its business scope includes: the first type of value-added telecommunications services; The second kind of value-added telecommunications services, etc. Enterprise investigation shows that the company is jointly held by Lianxiang and others.Lianxiang Co., Ltd. and others set up a new digital technology company. The enterprise search APP shows that recently, Zhejiang Lianxi Digital Technology Co., Ltd. was established, with Li Xiaoliang as the legal representative and a registered capital of 10 million yuan. Its business scope includes: the first type of value-added telecommunications services; The second kind of value-added telecommunications services, etc. Enterprise investigation shows that the company is jointly held by Lianxiang and others.

Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Musk moved SpaceX headquarters to the Starbase in Texas.Zheshang Securities: It does not rule out the possibility of lowering the RRR and cutting interest rates at the same time before the end of the year. Zheshang Securities research report said that this central economic work conference went further on the basis of the previous Politburo meeting, and clearly put forward "timely RRR reduction and interest rate reduction". Combined with the central bank's statement on the RRR reduction space in late September, it is expected that there will be a 50-basis-point RRR reduction before the end of the year, which will greatly promote interest rate reduction in the first quarter of next year, and even does not rule out the possibility of simultaneous RRR reduction and interest rate reduction before the end of the year. We are optimistic that the equity market and the bond market will step out of the double bull market in the process of gradual policy development.

Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Shunkong developed 50 million yuan to set up an industrial investment company. According to the enterprise survey APP, recently, Guangdong Shunkong Qingxun Industrial Investment Co., Ltd. was established with Liang Weifeng as the legal representative and a registered capital of 50 million yuan. Its business scope includes: sales of eco-environmental materials; Sales of building materials; Sales of new membrane materials; Sales of synthetic materials, etc. Enterprise investigation shows that the company is wholly owned by Shunkong Development.Hailian Jinhui invested 20 million yuan to set up an auto parts company in Wuhu. According to the enterprise search APP, Wuhu Hailian Jinhui Auto Parts Co., Ltd. was established recently, with the legal representative of Wang Weichao and the registered capital of 20 million yuan. Its business scope includes: manufacturing of auto parts and accessories; Mold manufacturing; Sales of metal materials; New material technology research and development, etc. Enterprise investigation shows that the company is indirectly wholly-owned by Hailian Jinhui.